Conference call a couple months back assured all that balance sheet was sound and no debt. We're really in the dark here about just this quarter. CFO also said that any hits taken on account of euro weakness would be offset by fact that they buy, acquire, not only sell, with Euros.
I can't imagine that things went south the extent that recent price drop suggests. I think the re-indexing in May may have crippled Israeli stocks in the short run in a way I hadn't anticipated. All the press said that Israeli stocks would benefit though there was no indication how long that would take. I believe in GIVN and will probably pick up some more at this price level. When FDA clearance is obtained here a year or so, this stock will be worth SO much more.